From: Hepatic profile analyses of tipranavir in Phase II and III clinical trials
Parameter | HR1 (p-value) | 95% Confidence Interval |
---|---|---|
Treatment group: | 2.77 (<0.0001) | 1.71, 4.48 |
TPV/r v CPI/r | ||
HBV or HCV co-infection: | 2.00 (0.0057) | 1.22, 3.27 |
yes vs. no | ||
ALT/AST at baseline: | 2.05 (0.0709) | 0.94, 4.48 |
Grade ≥2 vs. ≤Grade 1 | ||
CD4+ cells at baseline: | 1.46 (0.0643) | 0.98, 2.18 |
>200 vs. ≤200 cells/mm3 |